Store
The Market for Molecular Point-of-Care (mPOC), 2022
Publication Date: March 24, 2022
Tags: COVID-19, Diagnostic Instruments, Molecular Diagnostics, Point-of-Care (POC) Testing
Pages: 125
SKU: 22-018
Kalorama Information’s The Market for Molecular Point-of-Care (mPOC), 2022 is an invaluable resource for stakeholders in the mPOC market, providing the most current and comprehensive analysis of the industry’s trends, technologies, and market dynamics, including market sizing, forecasting, trend analysis, and competitive landscape evaluation.
Report Highlights:
- Market Overview:
- Detailed analysis of the market for molecular point of care tests utilizing PCR or other molecular technologies known for their rapid turnaround times and suitability for near-patient settings.
- Examination of major industry players such as Abbott, Roche, and Quidel, along with many emerging competitors since our last report.
- Technological Advancements:
- Focus on mPOC systems that deliver faster and more accurate results compared to traditional lab-based tests and existing point of care systems.
- Exploration of ongoing developments and menu expansions within the mPOC segment.
- Defining mPOC:
- Clear definition of mPOC systems, characterized by their ability to perform DNA and RNA testing on compact devices designed for use outside of reference labs.
- Emphasis on the rapid result times, typically within the duration of an office visit or bedside consultation, facilitated by user-friendly cartridges and minimal preparation steps.
- Impact of COVID-19:
- In-depth analysis of how the COVID-19 pandemic has accelerated the adoption and development of mPOC systems.
- Coverage of the significant role rapid PCR testing has played during the pandemic, meeting the demand for timely and accurate diagnostics.
Market Insights:
- Data and Competitive Analysis:
- Detailed data on current mPOC systems and competitor landscape.
- Market size and growth projections from 2021 to 2026, including specific focus on the COVID-19 mPOC market.
- Breakdown of market share by vendor, geographic regions, and market segments.
- Segment Analysis:
- Detailed segmentation of the molecular point of care market, including respiratory and other applications.
- Analysis of the respiratory segment, covering specific conditions like Flu, RSV, and Strep.
- Geographic and segment breakouts of market data for 2021, including North America, Europe, APAC, and Rest of World (RoW).
Strategic Insights:
- Trends and Developments:
- Exploration of key trends such as menu expansion, disease statistics, and the competitive landscape amidst the COVID-19 crisis.
- Examination of immunoassay competition and enhancements, emerging markets, and recent journal studies on the efficacy of mPOC systems.
Table: Molecular Point of Care Market, 2021-2026 (in millions $)
| Year | Revenues | Growth |
| 2021 | $XX Million | XX% |
| 2022 | $XX Million | XX% |
| 2023 | $XX Million | XX% |
| 2024 | $XX Million | XX% |
| 2025 | $XX Million | XX% |
| 2026 | $XX Million | XX% |
| CAGR | $XX Million | XX% |
Source: Kalorama Information
For further details and to purchase directly, please contact us.
Table of Contents
Chapter One: Executive Summary
- Figure 1-1: Molecular Point of Care Market, 2021-2026
Where is Molecular Point of Care in 2021?
Molecular Point of Care Market Analysis
- Figure 1-2: mPOC Market by Disease Indication, 2020 (%; Respiratory, Other)
Market Observations
“Near-Patient” Molecular Systems Market
- Figure 1-3: mPOC and Near-Patient Market, 2021-2026
- Table 1-1: Near Patient Molecular Systems Market: 2021-2026 ($M)
Current Trends
Molecular Point-of-Care Diagnostics Defined
Usage of Molecular Point of Care
Leading mPOC Platforms
- Table 1-2: Molecular POC Diagnostic Platforms/ Technologies
Trends
Scope and Methodology
Chapter Two: Molecular Point-of-Care Market Development and Trends
COVID-19 and Molecular POC
- Table 2-1: Molecular POC COVID-19 Emergency Authorizations
CDC Initial Response, Long Term Situation
COVID-19’s Unique Challenge
BARDA Directs Funding to mPOC
Recent Regulatory Developments
Consortia, Funding, Prizes
Deals
- Table 2-2: Deals in Molecular Point of Care
Advantages and Disadvantages of Molecular Point of Care
- Table 2-3: Disadvantages of Molecular Point of Care, by Setting
Justification: The Sensitivity/Specificity Argument
New Systems and Menu Expansion
Mesa Biotech Strep A Approval
Combination Tests Enter Market: SARS-CoV-2, Flu A, Flu B, and RSV
STI Continues to Be a Growth Area
Deals, Investment in mPOC Systems
Thermo Acquires Mesa Biotech
EU Researchers Awarded €3M to Develop POC Molecular Tests
Scope Fluidics AST System Sees Investment
China as a POC Market
Common Tests and Analytes in POC Diagnostics
Component Technologies of Molecular Point-of-Care Diagnostics
Microfluidics
qPCR
Microarrays
Isothermal Amplification
Test Automation
Primers and Probes
Detection
Next-Generation Sequencing
Molecular Diagnostics
Real-Time PCR (qPCR)
Isothermal Amplification Methods
Line Probe Assays
Next-Generation Sequencing
Applications and Potential Applications for Molecular Point-of-Care
Major Testing Applications for Molecular POC Diagnostics
Influenza
Reclassification of RIDTs
Hospital-Acquired Infections (HAIs)
Strep A
Respiratory Syncytial Virus (RSV)
Emerging Applications
Zika
Other Respiratory Infections
Group B Streptococcus
Human Papillomavirus
Herpes Simplex Virus
Vaginitis
Malaria
Other Tropical and Neglected Diseases
Cancer
European Device Regulations Nearing
Chapter Three: Market Analysis
Molecular Point of Care Market Analysis
- Table 3-1: Molecular Point of Care Market: 2021-2026
- Table 3-2: Molecular Point of Care Market Share by Vendor, 2021 ($M, %)
- Figure 3-1: Molecular Point of Care Market Share by Vendor, 2021 (%)
- Table 3-3: Geographic Breakout of the Molecular Point of Care Market, 2021 (N. America, Europe, APAC, RoW)
- Table 3-4: Segment Breakout of Molecular Point of Care Market, 2021 (Respiratory vs. Other)
- Figure 3-2: Breakout of Molecular Point of Care Market, 2021 (%; Respiratory, Other)
“Near Patient Molecular” Market
- Table 3-5: Near Patient Molecular Systems Market: 2021-2026
Market Share Near Patient
- Figure 3-3: Market Share, Near Patient Molecular Testing, 2021
Chapter Four: Company Profiles
Abbott Laboratories
Aidian Oy
Akonni Biosystems
binx health, inc.
Biocartis NV
bioMérieux SA
Cepheid (Danaher)
Molecular Healthcare-Acquired Infection (HAI) Testing
Molecular Sexual Health and Women’s Health Testing
Molecular Critical Infectious Disease Testing
Molecular Oncology/Genetics Testing
Credo Diagnostics
Curetis NV (OpGen)
DiaSorin S.p.A
GenMark Diagnostics (Roche)
Greiner Bio-One GmbH
Meridian Bioscience, Inc.
Mesa Biotech, Inc. (Thermo)
QIAGEN NV
QuantuMDx Group
Quidel Corporation
Roche
Sekisui Diagnostics LLC
T2 Biosystems
Related products
IVD Market Trends Report, March 2023
March 17, 2023
Diagnostic testing remains a cornerstone in healthcare, aiding physicians in diagnosis and providing crucial information for treatments like precision medicine. As we navigate the aftermath of the COVID-19 pandemic, the IVD market is evolving, driven by new products, shifts in global health spending, regulatory updates, and changing disease trends. Despite these shifts, the IVD market…
$3,000.00 – $4,500.00
The Worldwide Market for Clinical Laboratory Services, 9th Edition
June 25, 2024
Understanding the clinical laboratory market is crucial for effective business planning. The Worldwide Market for Clinical Laboratory Services, 9th Edition answers essential questions such as the size of the service market for clinical testing, the types of tests that are in demand, and the future trajectory of this market 2023-2028. It also identifies the companies…
$5,000.00 – $7,500.00
In Vitro Diagnostic (IVD) Trends and Market Update: March 2024
March 26, 2024
Explore the latest trends and developments in the in vitro diagnostic (IVD) market with Kalorama Information’s comprehensive report, In Vitro Diagnostic (IVD) Trends and Market Update: March 2024. Gain insights into key growth segments, industry trends, and emerging technologies shaping the future of IVD.
The report offers updated data analysis based on Kalorama Information’s annual…
$5,000.00 – $7,875.00
